PLEASE FIND BELOW THE 2019 FALL CONFERENCE AGENDA
Wednesday, October 16, 2019
8:00 AM - 8:30 AM
Registration, welcome coffee and networking
8:30 AM - 8:40 AM
Chairman's Opening Address
Eldora Ellison, Director, Sterne Kessler Goldstein & Fox
8:40 AM - 9:10 AM
US Patent Law Outlook: What Major Changes are on the 2020 Horizon, and will the US Ease Limits on Patent-Eligible Inventions?
Charles Larsen, Partner, White & Case
9:10 AM - 9:35 AM

How is AI Disrupting the Patent Strategies of Life Sciences Companies - What are the Likely Implications of AI on Patenting and Licensing Strategies?
Karen Potter, Partner, Morrison & Foerster
Anna Yuan, Associate, Morrison & Foerster

9:35 AM - 10:00 AM

New Challenges to Patent Protection for Pharmaceuticals and Biologics
David Gindler, Partner, Milbank

10:00 AM - 10:20 AM

Changes to Patented Medicines Pricing in Canada
Nancy Pei, Partner, Smart & Biggar

10:20 AM - 10:40 AM

Antibody Patent Infringement Lawsuit in Japan: Amgen v. Sanofi
Tokyo District Court Affirmed Infringement in Amgen v. Sanofi
How to claim Antibody?  - by Function, Amino Acid Sequence, or CDR?
Broad Claim?  - Enablement Requirement of Antibody Patent

Takanori Abe, Patent Attorney, Abe & Partners
10:40 AM - 11:10 AM
Morning Coffee and Networking in the Exhibition Hall
11:15 AM - 12:00 PM

Addressing Second Medical Use Infringement

Moderator: 
Alison Maddeford, IP Litigation Partner, Thermo Fisher Scientific

Panellists:
Bethan Hopewell, Partner, Powell Gilbert
Joel Coles, Senior Associate, Powell Gilbert
Glyn Truscott, Partner - UK & European Patent Attorney, Elkington + Fife

12:00 PM - 12:45 PM

Is the Existing IP System Fit for Purpose?

Panellists:
Sarah Wang, CEO and Founder, AppoG
Thomas Malone, IP Corporate Counsel , DuPont Industrial Biosciences
Robert Bernstein, Senior Director, Intellectual Property, Plexxikon
Rebecca Lin, VP of Strategy and Global Business Development, Potrero
Steven J. Sarussi, Partner, McDonnell Boehnen Hulbert & Berghoff

12:45 PM - 1:45 PM
Lunch and networking in the Exhibition Hall 
1:45 PM - 2:00 PM
Roundtable Discussion Groups 
 
Taking part in these discussions offers delegates and speakers the opportunity to focus on topics of specific interest, within a small group. 40-45 minutes is set aside for each rotation – and delegates may choose two discussion tables. The roundtable discussion groups give delegates even more opportunity to share knowledge and opinion, and ends with a moderator round-up of key findings, providing delegates with an insight into all eight topics.
 
SESSION 1 - PLEASE CHOOSE YOUR FIRST TABLE FROM THE FOLLOWING:
2:00 PM - 2:44 PM
Best Practice in IP Portfolio Management
William Lambert, Partner, Sheppard Mullin
CAR-T and other Immunotherapies
Iain Armstrong, Partner, HGF
How do we Ensure Effective Protection of Antibodies?
Filko Prugo, Partner, Chair, Life Sciences IP Litigation, Ropes & Gray
Henry Huang, Associate, Ropes & Gray
IP considerations in Precision Medicine
Glyn Truscott, Partner - UK & European Patent Attorney, Elkington + Fife
Life Sciences Patents Open Clinic: Solving in-house counsel challenges
Nick Bassil, Partner, Kilburn & Strode 
Prior Art: Examining the Implications of Trade Secrets Protection
John Sninsky, Independent Consultant in Translational Sciences
 
2:45 PM - 3:30 PM
Best Practice in IP Portfolio Management
William Lambert, Partner, Sheppard Mullin
CAR-T and other Immunotherapies
Iain Armstrong, Partner, HGF
How do we Ensure Effective Protection of Antibodies?
Filko Prugo, Partner, Chair, Life Sciences IP Litigation, Ropes & Gray
Henry Huang, Associate, Ropes & Gray
IP considerations in Precision Medicine
Glyn Truscott, Partner - UK & European Patent Attorney, Elkington + Fife
Life Sciences Patents Open Clinic: Solving in-house counsel challenges
Nick Bassil, Partner, Kilburn & Strode 
Prior Art: Examining the Implications of Trade Secrets Protection
John Sninsky, Independent Consultant in Translational Sciences
 
3:30 PM - 4:00 PM
Afternoon tea and networking in the Exhibiton Hall
4:00 PM - 4:25 PM
How do Business People Perceive IP Management and How can you Better Engage Internal Decision Makers with the IP Strategy Discussion and Day to Day Operations
Rebecca Lin, VP of Strategy and Global Business Development, Potrero
4:25 PM - 5:00 PM
Innovative IP Strategies for Life Sciences: Best Practice in Managing Pharma and Biotech IP in the Age of Big Data and Precision Medicine
 
Moderator: 
Peter Scott, Group Publisher & Editor-in-Chief, World IP Review
 
Panellists: 
Danielle Pasqualone, VP, IP, Alector
John Sninsky, Independent Consultant in Translational Sciences 
Sarah Wang, CEO and Founder, AppoG
5:00 PM - 5:30 PM

IP Portfolio Management: In-house Counsel Day-to-Day Challenges in Prosecuting and Enforcing Patents

Moderator: 
Michael Wise, Partner, Perkins Coie

Panellists:
Linda Wu, Senior IP Counsel, Natera
Thomas Malone, IP Corporate Counsel, DuPont Industrial Biosciences
Kamrin MacKnight, Associate VP of Intellectual Property & Chief Patent Counsel, Codexis

5:45 PM
Chair’s Closing Remarks

Contact our team

For sponsoring: 
Kirsty Pocock
Commercial Director
+44 (0) 203 301 8211
 
 
For speaking: 
Sarah Gooding 
Head of Content
sgooding@newtonmedia.co.uk
+44 (0) 7957672202
For attending: 
Kate Wood
Delegate Sales Manager
+44 (0) 203 301 8232